Tarsus Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
from Tarsus Pharmaceuticals, Chief Commercial Officer, Neera Clase, and Head of IR, David Nakasone. Thank you so much for being here. You just reported the earnings last week. Neera, maybe take a minute to just walk us through what you showed, and what we should be looking forward to in the next couple months.
Yeah. Super excited about the quarter that we had in Q3. We were delivering on all cylinders, and what is really exciting is we had growth year-over-year, 64%. What drives that growth are a couple key things. One, we saw an increase in return on our DTC efforts. We saw also great impact of our Key Account Leaders or our sales team, really driving expansion of TAM and patient types. We also saw evidence release. We released 11 abstracts at the American Academy of Optometry with a lot of new data and insights, expanding patient use. Then finally, we had a nice tailwind with retreatment and refills.
Q3 is usually a little bit of a softer quarter seasonally. So, where in what you just mentioned should we expect to sort of continue into Q4 in 2027, and what was sort of a one-off or unique thing about the third quarter, if anything?
Yeah. We learned this past year that Q3 is typically very seasonal in terms of doctors being out of the office, patients being out of the office. We pulled forward some of our funds and our efforts into Q2, and what we actually found is some really good opportunities to mitigate the seasonal impact. So we saw a greater lift, and in effect, we also saw the synergies of our campaigns. Keep in mind, this year we also rolled out not only branded and unbranded DTC, but we also had a really significant social media campaign with John Cena, and that really introduced a whole new patient type, and we're excited about that, leveraging that with the synergies of our sales force.
We added 20 new KALs, and so that momentum really created some real nice tailwinds moving into the back half of this year and then coming into the new year.
Yeah, so when we think about 4Q, you raised your guidance slightly, but 4Q also has some seasonality with respect to holidays and things like that. So, how should we think about the sort of upper end and bottom end of that guidance that you gave, and sort of what could lead to that in the 4Q that we should be paying attention to Absolutely as we see the scripts?
Yeah. So, again, we're seeing really robust scripts. What we typically see in fourth quarter is, being that we are an NRX product, every quarter we reset. So, we do expect a little bit of seasonality too with doctors being out of the office, patients being out of the office, starting from Thanksgiving through the Christmas holiday. So, between now and then, a really nice, robust kind of finish, but there will be some time off and time out of the offices.
Or bad winter storms. Or bad winter storms that we can't forecast.
Always ready for that, but we feel really confident that we're going to meet the guidance.
Yeah. You mentioned the Key Account Leader team that's increased. How should we think about what impact that's already had, and then what's the timing around when that continues to have an impact in future growth?
Yeah. Think about it this way. They had their full first quarter in Q3, and as we think about moving into Q4 and into 2027, we're probably going to see a lot more efficiencies and effectiveness with this group. They're working on things like routing, frequency. They're looking at messaging. As we continue to refine that, we'll probably see greater ROI as well.
When we think about the current sort of prescriber base, you guys have characterized this in some ways as having sort of really high worth prescribers in a sense of like many per day, many per week, versus some of the sort of ones that you're still reaching out to, getting into the community setting, or just reach. When we think about the sort of lower end, but still regular prescribers that are maybe weekly, what's the effort and lift to get those into a daily prescriber that's really driving the growth that you've seen?
Yeah. A lot of this is about patient expansion and them seeing the value of the evidence that's out there. Again, we released a lot of good evidence, and now they're starting to also get into a habit in terms of understanding where they can diagnose and start to treat these patients across different patient types. So not just the patients that may provide with symptoms, but the asymptomatic patients who may need a more pristine ocular surface, as they are getting ready for things like surgery, as they are also concomitantly having other comorbidities. Now we're seeing more broadening of the patient types, or deepening, if you will.
Is that something you guys see in claims data that you can separate to see? Because I know we talked about this, Dave, early in the launch about the sort of different buckets of patients. Are you able to sort of see that you're sort of starting to penetrate the sort of non-DB patients?
Oh, absolutely. I think Neera kind of hit it on the head. We're seeing a lot of depth of prescribing, and we're also seeing it across all different types of patient segments.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
